Prognostic value of sarcopenia in patients with CKD


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. Evaluation of the prognostic role of sarcopenia in patients with CKD. Materials and methods. The study included 79 patients with an proven diagnosis of CKD and ah or cad. GFR was calculated using the CKD-EPI formula. The diagnosis of CKD was verified in accordance with the KDIGO recommendations; the diagnosis of sarcopenia - in accordance with the EWGSOP recommendations. Progression of CKD was determined as an increase in the CKD stage during the year. The end points were the presence of any cardiovascular events, including coronary intervention, and/or the death of the patient. For statistical analysis of the data obtained, the R language RStudio software (packages psych, epiR, ggplot2, dplyr) was used. Results. The mean age of patients was 74.97±8.27 years, CHF was detected in 34.2% of patients, and progression of CKD was detected in 40.5% of patients, of which 20.3% of patients had sarcopenia. a direct, reverse, significant relationship was found between the progression of CKD and the presence of sarcopenia in patients (P=0.043). 23 endpoints were registered. In patients with sarcopenia, there was a tendency to increase the IL-18 and IL-6 levels, and a decrease in the anti-inflammatory cytokine IL-io level. However, no differences were found in the IL-18 and IL-6 levels in patients with and without sarcopenia. The data obtained demonstrates that with an average log IL-18 level equal to 4.7, an increase by 1 leads to an increase in log IL-6 by 0.23. The logit regression model and or showed that the IL-18 level most influences the risk of the end points being studied. The risk of end-point development increases by 5.76 times when patients with CKD have high IL-18 levels. Conclusion. Thus, it can be concluded that anti-inflammatory system of interleukins has a greater prognostic value for patients with CKD and sarcopenia.

Full Text

Restricted Access

About the authors

A. V Sokolova

Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

PhD in Medical Sciences, Teaching Assistant at the Department of Propedeutics of Internal Diseases, Faculty of Pediatrics Moscow, Russia

D. O Dragunov

Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: tamops2211@gmail.com
PhD in Medical Sciences, Associate Professor at the Department of Propedeutics of Internal Diseases, Faculty of Pediatrics Moscow, Russia

G. P Arutyunov

Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Doctor of Medical Sciences, Professor, Corresponding Member of RAS, Head of the Department of Propaedeutics of Internal Diseases of the Faculty of Pediatrics Moscow, Russia

V. M Mitrokhin

Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

PhD in Medical Sciences, Associate Professor at the Department of Propedeutics of Internal Diseases, Faculty of Pediatrics Moscow, Russia

References

  1. Mahmood U, Healy H.G., Kark A., Cameron A., Wang Z., Abeysekera R., Hoy W.E. Spectrum (characteristics) of patients with chronic kidney disease (CKD) with increasing age in a major metropolitan renal service. BMC. Nephrol. 2017; 18(1).
  2. Bellasi A, Mangano M., Galassi A., Cozzolino M. CKD-MBD, cardiovascular involvement and prognosis. NCBI. 2017; 34(69): 150-161.
  3. Hallan S.I., Orth S.R. The Conundrum of Chronic Kidney Disease Classification and End-Stage Renal Risk Prediction in the Elderly - What Is the Right Approach? Nephron. Clin. Pract. 2010; 116(4): 307-316.
  4. Kim J.-K. Choi S.R., Choi M.J., Kim S.G., Lee Y.K., Noh J.W., Kim H.J., Song Y.R. Prevalence of and factors associated with sarcopenia in elderly patients with end-stage renal disease. Clin. Nutr. 2014; 33(1): 64-68. doi: 10.1016/j.clnu.2013.04.002
  5. Pereira R.A. Cordeiro A.C,Avesani C.M., Carrero J.J., Lindholm B.,Amparo F.C., Amodeo C., Cuppari L., Kamimura M.A. Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality. Nephrol. Dial. Transplant. 2015; 30(10): 1718-1725. doi: 10.1093/ndt/gfv133.
  6. Han E., Lee Y.H., Kim G., Kim S.R., Lee B.W., Kang E.S., Ahn C.W., Cha B.S. Sarcopenia is associated with albuminuria independently of hypertension and diabetes: KNHANES 2008-2011. Metabolism. 2016; 65(10): 1531-1540. doi: 10.1016/j.metabol.2016.07.003.
  7. Fahal I.H. Uraemic sarcopenia: aetiology and implications. Nephrol. Dial. Transplant. 2014; 29(9): 1655-1665. doi: 10.1093/ndt/gft070.
  8. D’Alessandro C., Piccoli G.B., Barsotti M., Tassi S., Giannese D., Morganti R., Cupisti A. Prevalence and Correlates of Sarcopenia among Elderly CKD Outpatients on Tertiary Care. Nutrients. 2018; 10(12): 1951. doi: 10.3390/nu10121951.
  9. Арутюнов А.Т. и др. Влияние лекарственных форм петлевого диуретика с различной скоростью высвобождения на ранний и отсроченный прогноз у пациентов с декомпенсацией кровообращения. Кардиология. 2014; 9: 54.
  10. Hruska K.A., Choi E.T., Memon I., Davis T.K., Mathew S. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr. Nephrol. 2010; 25(4): 769-778. doi: 10.1007/s00467-009-1337-0.
  11. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. N. Engl. J. Med. 2004; 351(13): 1296-1305. doi: 10.1056/NEJMoa041031.
  12. Rattanawong P. Kanitsoraphan C., Kewcharoen J., Riangwiwat T., Chongyangyuenvong P., Vutthikraivit W., Mannem S.R., Chung E.H. Chronic kidney disease is associated with increased mortality and procedural complications in transcatheter aortic valve replacement: a systematic review and meta-analysis. Catheter. Cardiovasc. Interv. 2019. doi: 10.1002/ccd.28102.
  13. Di Lullo L., House A, Gorini A., Santoboni A., Russo D., Ronco C. Chronic kidney disease and cardiovascular complications. Heart Fail. Rev. 2015; 20(3): 259-272,. doi: 10.1007/s10741-014-9460-9.
  14. Helena Oliveira Sa. A prevengao da Doenga Renal Cronica (DRC) ou A urgencia de uma politica nacional parao diagnostico e tratamento precoces. Port J. Nephrol. Hypert. 2013; (1): 9-12.
  15. Смирнов А.В., Шилов Е.М., Добронравов В.А., Каюков И.Т., Бобкова И.Н., Швецов М.Ю., Цыгин А.Н., Шутов А. М. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология. 2012; 1.
  16. Kidney International Supplements. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. ScienceDirect. com [Electronic resource]. URL: https://www.sciencedirect.com/journal/kidney-international-supplements/vol/3/issue/1 (accessed: 25.01.2018).
  17. Мареев В.Ю. et al. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Утверждены на Конгрессе ОССН 7 декабря 2012 года, на Правлении ОССН 31 марта 2013 и Конгрессе РКО 25 сентября 2013 года. Журнал сердечная недостаточность. 14; 7(81): 2013.
  18. Cruz-Jentoft A.J., Cruz-Jentoft A.J., Baeyens J.P, Bauer J.M., Boirie Y., Cederholm T., Landi F., Martin F.C., Michel J.P., Rolland Y., Schneider S.M., Topinkova E., Vandewoude M., Zamboni M. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4): 412-423. doi: 10.1093/ageing/afq034
  19. Rosenberg I.H. Sarcopenia: Origins and Clinical Relevance. J. Nutr. 1997; 127(5): 990S-991S.
  20. Foley R.N. et al. Kidney Function and Sarcopenia in the United States General Population: NHANES III. Am. J. Nephrol. 2007; 27(3): 279-286.
  21. Souza V.A. de et al. Sarcopenia in Chronic Kidney Disease. J. Bras. Nefrol. 2015; 37(1). doi: 10.5935/0101-2800.20150014.
  22. Moorthi R.N., Avin K.G. Clinical relevance of sarcopenia in chronic kidney disease: Curr. Opin. Nephrol. Hypertens. 2017; 26(3): 219-228. doi: 10.1097/MNH.0000000000000318.
  23. Zhou Y., Hellberg M., Svensson P., Hoglund P., Clyne N. Sarcopenia and relationships between muscle mass, measured glomerular filtration rate and physical function in patients with chronic kidney disease stages 3-5. Nephrol. Dial. Transplant. 2018; 33(2): 342-348. doi: 10.1093/ndt/gfw466.
  24. Dunlap W.A., Purnell W.D., McPherson S.D. A new synthetic absorbable suture for ophthalmic surgery: laboratory and clinical evaluation. South. Med. J. 1976; 69(5): 588-592.
  25. Su H., Lei C.-T., Zhang C. Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update Front. Immunol. 2017; 8.
  26. Pecoits-Filho R. et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 2003; 41(6): 1212-1218.
  27. Liang H., Xu F., Zhang T., Huang J., Guan Q., Wang H., Huang Q. Inhibition of IL-18 reduces renal fibrosis after ischemia-reperfusion. Biomed. Pharmacother. 2018; 106: 879-889. doi: 10.1016/j.biopha.2018.07.031.
  28. Wang S., Chen F., Yang S., Shi J. Interleukin-18: A Predictive Marker of Major Adverse Cardiovascular Events in Hemodialysis Patients. Int. Heart. J. 2018; 59(4): 786-790. doi: 10.1536/ihj.17-154.Formanowicz D., Wanic-Kossowska M., Pawliczak E., Radom M., Formanowicz P. Usefulness of serum interleukin-18 in predicting cardiovascular mortality in patients with chronic kidney disease - systems and clinical approach. Sci. Rep. 2016; 5(1). Doi: 10.1038/ srep18332.
  29. Hirai K., Ookawara S., Morishita Y. Sarcopenia and Physical Inactivity in Patients With Chronic Kidney Disease. Nephro-Urol. Mon. 2016; 8(3). doi: 10.5812/numonthly.37443.
  30. Derbre F. Gratas-Delamarche A., Gomez-Cabrera M.C., Vina J. Inactivity-induced oxidative stress: A central role in age-related sarcopenia? Eur. J. Sport Sci. 2014; 14(1): S98-S108. doi: 10.1080/17461391.2011.654268.
  31. Schaap L.A., Pluijm S.M., Deeg D.J., Harris T.B., Kritchevsky S.B., Newman A.B., Colbert L.H., Pahor M., Rubin S.M., Tylavsky F.A., Visser M. Higher Inflammatory Marker Levels in Older Persons: Associations With 5-Year Change in Muscle Mass and Muscle Strength. J. Gerontol. A. Biol. Sci. Med. Sci. 2009; 64(11): 1183-1189. doi: 10.1093/gerona/glp097.
  32. Schaap L.A., Pluijm S.M., Deeg D.J., Visser M. Inflammatory Markers and Loss of Muscle Mass (Sarcopenia) and Strength. Am. J. Med. 2006; 119(6): 526. e9-526.e17. doi: 10.1016/j.amjmed.2005.10.049.
  33. Honda H., Qureshi A.R., Axelsson J., Heimburger O., Suliman M.E., Barany P., Stenvinkel P., Lindholm B. Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am. J. Clin. Nutr. 2007; 86(3): 633-638. doi: 10.1093/ajcn/86.3.633.
  34. Cesari M., Kritchevsky S.B., Baumgartner R.N., Atkinson H.H., Penninx B.W., Lenchik L., Palla S.L., Ambrosius W.T., Tracy R.P., Pahor M. Sarcopenia, obesity, and inflammation - results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study. Am. J. Clin. Nutr. 2005; 82(2): 428-434. doi: 10.1093/ajcn.82.2.428.
  35. Bano G., Trevisan C., Carraro S., Solmi M., Luchini C., Stubbs B., Manzato E., Sergi G., Veronese N. Inflammation and sarcopenia: A systematic review and meta-analysis. Maturitas. 2017; 96: 10-15. doi: 10.1016/j.maturitas.2016.11.006.
  36. Wright J., Hutchison A. Cardiovascular disease in patients with chronic kidney disease. Vasc. Health Risk Manag. 2009; 5: 713-722.
  37. Tesar V Cardiovascular complications in patients with chronic renal insufficiency and chronic kidney failure. Vnitr. Lek. 2003; 49(5): 383-387.
  38. Lindholm B. et al. Influence of different treatments and schedules on the factors conditioning the nutritional status in dialysis patients. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc. 1998; 13(6): 66-73.
  39. de Lusignan S., Chan T., Stevens P., O’Donoghue D., Hague N., Dzregah B., Van Vlymen J., Walker M., Hilton S. Identifying patients with chronic kidney disease from general practice computer records. Fam. Pract. 2005; 22(3): 234-241.
  40. Hanatani S. et al. Non-invasive testing for sarcopenia predicts future cardiovascular events in patients with chronic kidney disease. Int. J. Cardiol. 2018; 268: 216-221. doi: 10.1016/j.ijcard.2018.03.064.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies